National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

indium In 111-CMD-193
A radiolabeled antibody-targeted antineoplastic antibiotic consisting of the enediyne antibiotic calicheamicin conjugated with anti-Lewis Y antibody and labeled with indium In 111. In 111 CMD-193 binds to Lewis Y antigen-expressing tumor cells via its antibody moiety and is internalized; subsequently, the calicheamicin moiety binds to the minor groove of tumor cell DNA, causing double-strand DNA breaks, the inhibition of DNA synthesis, and apoptosis. The indium In 111 radiolabel allows the detection of CMD-193 distribution and tumor localization using gamma scintigraphy. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:In 111 CMD-193



Previous:indium In 111 CHX-A DTPA trastuzumab, indium In 111 ibritumomab tiuxetan, indium In 111 monoclonal antibody BrE-3, indium In 111 monoclonal antibody huPAM4, indium In 111 pentetate
Next:indium In 111-labeled autologous peripheral blood mononuclear cells, indium In 111-labeled autologous polymorphonuclear leukocytes, Indocin, indocyanine green solution, indole-3-carbinol

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov